fibrinopeptide


Also found in: Dictionary, Thesaurus.

fibrinopeptide

 [fi″brĭ-no-pep´tīd]
either of two peptides (A and B) split off from fibrinogen during blood clotting by the action of thrombin.

fi·brin·o·pep·tide

(fī'brin-ō-pep'tīd),
One of two pairs of peptides (A and B) released from the amino-terminal ends of 2α- (or Aα-) and 2β- (or Bβ-)chains of fibrinogen by the action of thrombin to form fibrin; they have a vasoconstrictive effect.

fibrinopeptide

/fi·bri·no·pep·tide/ (fi-brin″o-pep´tīd) either of two peptides (A and B) split off from fibrinogen during coagulation by the action of thrombin.

fibrinopeptide

[fī′brinōpep′tīd]
Etymology: L, fibra + Gk, peptein, to digest
either of two peptides (A and B) split off from fibrinogen by the action of thrombin. See also fibrinogen, thrombin.

fi·brin·o·pep·tide

(fī'brin-ō-pep'tīd)
One of two pairs of peptides (A and B) released from the amino-terminal ends of 2α- and 2β-chains of fibrinogen by the action of thrombin to form fibrin; has a vasoconstrictive effect.

fibrinopeptide

either of two peptides (A and B) split off from fibrinogen during blood clotting by the action of thrombin.
References in periodicals archive ?
After 25 min, the resulting clot was recovered by winding around a glass rod; the supernatant was retained for fibrinopeptide isolation.
Each fibrinogen molecule releases up to 2 fibrinopeptide A and B molecules (38, 39), giving molar concentrations of fibrinopeptides among the most abundant serum components.
2; FPA, fibrinopeptide A; TAT, thrombin-antithrombin; PAI, plasminogen activator inhibitor; vWF, von Willebrand factor; t-PA; tissue plasminogen activator; TM, thrombomodulin; S-TM, soluble thrombomodulin; PAF, platelet activator factor; TNF, tumor necrosis factor; and TFPI, tissue factor pathway inhibitor.
The use of fibrinopeptide A as a marker of fibrin formation is limited because of preanalytical and technical difficulties (10).
His work has involved the use of markers of thrombosis such a fibrinopeptide A, F1.
The mechanism of the bleeding tendency is due to fibrinogen alterations that inhibit fibrinopeptide release or fibrin monomer polymerization, leading to poor clot formation.
Studies evaluating measures of hemostasis activation, such as the plasma level of fibrinopeptide A, which is cleaved from fibrinogen by thrombin, suggest that even asymptomatic nephrotic patients have evidence of ongoing coagulation.
The study will test for the presence of urinary fibrinopeptide B (FPB) as a marker for active VTE, as well as a tool to monitor the effectiveness of anti-coagulant therapy.
It was reported that infusion of 5-FU increased levels of plasma endothelin-1 and fibrinopeptide A and decreased protein C levels.
26) Thrombin mediates fibrin clot formation by cleaving 2 molecules each of fibrinopeptide A and fibrinopeptide B from fibrinogen, producing fibrin monomer.
The extension is modeled after fibrinopeptide B to facilitate renal filtration, contains D-amino acids to prevent proteolytic breakdown, and can eventually be released from the partially degraded substrates by photocleavage to generate a reporter with fixed molecular mass.